ArticleFrontiers in immunology2018
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- A side-by-side biophysical comparison of five single-domain antibody scaffolds used for synthetic display libraries.The Journal of biological chemistry · 2026Article
- Robust production of heavy-chain-only antibodies in mice by CRISPR/Cas mediatedNational science review · 2026Article
- Review
- Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in anFrontiers in immunology · 2025Article
- Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability.Computational and structural biotechnology journal · 2025Article
- Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire.Nature communications · 2024Article
- Characterization of plant produced VBiotechnology reports (Amsterdam, Netherlands) · 2024Article
- Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.International journal of molecular sciences · 2024Article
- Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Next generation of multispecific antibody engineering.Antibody therapeutics · 2024Review
- Development of a latex agglutination test based on VH antibody fragment for detection of Streptococcus suis serotype 2.PloS one · 2024Article
- Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.Signal transduction and targeted therapy · 2023Article
- A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.Oncoimmunology · 2023Article
- Anti-BCMA novel therapies for multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Review
- [Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm.Journal of the American Chemical Society · 2022Article
- A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.Oncoimmunology · 2022Article
- Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy.Frontiers in immunology · 2022Article
- A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Heavy chain-only antibodies (HCAbs) do not associate with light chains and their V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.